O	0	4	Anti
O	4	5	-
O	5	10	tumor
O	11	19	activity
O	20	22	of
B-intervention	23	35	capecitabine
O	36	39	and
B-control	40	51	vinorelbine
O	52	54	in
O	55	63	patients
O	64	68	with
O	69	82	anthracycline
O	82	83	-
O	84	87	and
O	88	94	taxane
O	94	95	-
O	95	105	pretreated
O	106	116	metastatic
O	117	123	breast
O	124	130	cancer
O	130	131	:
O	132	140	findings
O	141	145	from
O	146	149	the
O	150	155	EORTC
O	156	161	10001
O	162	172	randomized
O	173	178	phase
O	179	181	II
O	182	187	trial
O	187	188	.

O	189	192	The
O	193	196	aim
O	197	199	of
O	200	204	this
O	205	215	randomized
O	216	221	phase
O	222	224	II
O	225	230	study
O	231	234	was
O	235	237	to
O	238	246	evaluate
O	247	250	the
O	251	255	anti
O	255	256	-
O	256	261	tumor
O	262	270	activity
O	271	274	and
O	275	281	safety
O	282	284	of
O	285	297	capecitabine
O	298	301	and
O	302	313	vinorelbine
O	314	316	in
B-eligibility	317	325	patients
I-eligibility	326	330	with
I-eligibility	331	341	metastatic
I-eligibility	342	348	breast
I-eligibility	349	355	cancer
I-eligibility	356	366	pretreated
I-eligibility	367	371	with
I-eligibility	372	379	taxanes
I-eligibility	380	383	and
I-eligibility	384	398	anthracyclines
O	398	399	.

O	400	402	We
O	403	410	planned
O	411	413	to
O	414	423	randomize
B-total-participants	424	426	72
O	427	435	patients
O	436	438	to
O	439	451	capecitabine
O	452	456	1250
O	457	459	mg
O	459	460	/
O	460	461	m
O	461	462	(
O	462	463	2
O	463	464	)
O	465	471	orally
O	472	475	bid
O	476	480	days
O	481	482	1
O	482	483	-
O	483	485	14
O	486	488	or
O	489	500	vinorelbine
O	501	503	30
O	504	506	mg
O	506	507	/
O	507	508	m
O	508	509	(
O	509	510	2
O	510	511	)
O	512	513	i
O	513	514	.
O	515	516	v
O	516	517	.
O	518	522	days
O	523	524	1
O	525	528	and
O	529	530	8
O	530	531	,
O	532	536	both
O	537	542	given
O	543	548	every
O	549	550	3
O	551	556	weeks
O	556	557	.

O	558	561	The
O	562	567	study
O	568	571	was
O	572	579	stopped
O	580	583	due
O	584	586	to
O	587	591	poor
O	592	599	accrual
O	600	604	with
O	605	607	47
O	608	616	patients
O	617	625	enrolled
O	625	626	.

B-outcome	627	636	Responses
O	637	641	were
O	642	646	seen
O	647	649	in
B-iv-bin-abs	650	651	2
O	651	652	/
B-intervention-participants	652	654	23
O	655	663	patients
O	664	671	treated
O	672	676	with
O	677	689	capecitabine
O	690	691	(
B-iv-bin-percent	691	692	8
I-iv-bin-percent	692	693	.
I-iv-bin-percent	693	694	7
I-iv-bin-percent	694	695	%
O	695	696	;
O	697	699	95
O	699	700	%
O	701	703	CI
O	704	705	1
O	705	706	.
O	706	707	1
O	707	708	-
O	708	710	29
O	710	711	.
O	711	712	0
O	712	713	)
O	714	717	and
B-cv-bin-abs	718	719	3
O	719	720	/
B-control-participants	720	722	24
O	723	731	patients
O	732	739	treated
O	740	744	with
O	745	756	vinorelbine
O	757	758	(
B-cv-bin-percent	758	760	12
I-cv-bin-percent	760	761	.
I-cv-bin-percent	761	762	5
I-cv-bin-percent	762	763	%
O	763	764	;
O	765	767	95
O	767	768	%
O	769	771	CI
O	772	773	2
O	773	774	.
O	774	775	7
O	775	776	-
O	776	778	32
O	778	779	.
O	779	780	4
O	780	781	)
O	781	782	.

B-outcome	783	789	Median
I-outcome	790	801	progression
I-outcome	801	802	-
I-outcome	802	806	free
I-outcome	807	815	survival
O	816	819	was
B-iv-cont-median	820	821	2
I-iv-cont-median	821	822	.
I-iv-cont-median	822	823	8
O	824	827	and
B-cv-cont-median	828	829	2
I-cv-cont-median	829	830	.
I-cv-cont-median	830	831	6
I-cv-cont-median	832	838	months
O	838	839	,
O	840	843	and
B-outcome	844	850	median
I-outcome	851	858	overall
I-outcome	859	867	survival
O	868	871	was
B-iv-cont-median	872	873	9
I-iv-cont-median	873	874	.
I-iv-cont-median	874	875	3
O	876	879	and
B-cv-cont-median	880	882	11
I-cv-cont-median	882	883	.
I-cv-cont-median	883	884	0
I-cv-cont-median	885	891	months
O	891	892	,
O	893	895	in
O	896	899	the
O	900	912	capecitabine
O	913	916	and
O	917	928	vinorelbine
O	929	933	arms
O	933	934	,
O	935	947	respectively
O	947	948	.

O	949	954	There
O	955	958	was
O	959	963	more
B-outcome	964	975	hematologic
I-outcome	976	984	toxicity
O	984	985	,
B-outcome	986	999	neurotoxicity
O	999	1000	,
O	1001	1004	and
B-outcome	1005	1011	nausea
I-outcome	1011	1012	/
I-outcome	1012	1020	vomiting
O	1021	1025	with
O	1026	1037	vinorelbine
O	1038	1041	and
O	1042	1046	more
B-outcome	1047	1055	diarrhea
O	1056	1059	and
B-outcome	1060	1064	hand
I-outcome	1064	1065	-
I-outcome	1065	1069	foot
I-outcome	1070	1078	syndrome
O	1079	1083	with
O	1084	1096	capecitabine
O	1096	1097	.

O	1098	1101	The
O	1102	1106	anti
O	1106	1107	-
O	1107	1112	tumor
O	1113	1121	activity
O	1122	1124	of
O	1125	1137	capecitabine
O	1138	1141	and
O	1142	1153	vinorelbine
O	1154	1159	seems
O	1160	1162	to
O	1163	1165	be
O	1166	1176	comparable
O	1176	1177	,
O	1178	1181	but
O	1182	1185	the
O	1186	1194	toxicity
O	1195	1203	profiles
O	1204	1207	are
O	1208	1217	different
O	1217	1218	.
